- Home
- OSBC vs ETNB Comparison
OSBC vs ETNB Comparison
Compare OSBC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSBC
- ETNB
- Stock Information
- Founded
- OSBC 1981
- ETNB 2018
- Country
- OSBC United States
- ETNB United States
- Employees
- OSBC N/A
- ETNB N/A
- Industry
- OSBC Major Banks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- OSBC Finance
- ETNB Health Care
- Exchange
- OSBC Nasdaq
- ETNB Nasdaq
- Market Cap
- OSBC 838.3M
- ETNB 867.4M
- IPO Year
- OSBC N/A
- ETNB 2019
- Fundamental
- Price
- OSBC $17.95
- ETNB $7.94
- Analyst Decision
- OSBC Buy
- ETNB Buy
- Analyst Count
- OSBC 4
- ETNB 7
- Target Price
- OSBC $18.75
- ETNB $30.33
- AVG Volume (30 Days)
- OSBC 198.6K
- ETNB 800.5K
- Earning Date
- OSBC 01-22-2025
- ETNB 11-07-2024
- Dividend Yield
- OSBC 1.32%
- ETNB N/A
- EPS Growth
- OSBC N/A
- ETNB N/A
- EPS
- OSBC 1.85
- ETNB N/A
- Revenue
- OSBC $264,069,000.00
- ETNB N/A
- Revenue This Year
- OSBC N/A
- ETNB N/A
- Revenue Next Year
- OSBC N/A
- ETNB N/A
- P/E Ratio
- OSBC $9.83
- ETNB N/A
- Revenue Growth
- OSBC N/A
- ETNB N/A
- 52 Week Low
- OSBC $13.00
- ETNB $7.00
- 52 Week High
- OSBC $19.37
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- OSBC 47.91
- ETNB 44.02
- Support Level
- OSBC $18.09
- ETNB $7.44
- Resistance Level
- OSBC $18.63
- ETNB $8.09
- Average True Range (ATR)
- OSBC 0.38
- ETNB 0.44
- MACD
- OSBC -0.13
- ETNB -0.06
- Stochastic Oscillator
- OSBC 8.25
- ETNB 22.47
About OSBC Old Second Bancorp Inc.
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company's revenue consists of interest, commission, payments, and other income.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).